Jun 2026 (Q2 FY26) — Aug 6, 2026
Teleflex Q2 FY26 — Strong Vascular & Surgical Performance Amidst Interventional Integration Challenges
Read the full callTeleflex (TFX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Teleflex earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 570 | +28.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.8 | −7.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 99.7 | −18.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
9 of 13 judged targets kept · 28 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Freesolve BIOMAG-III U.S. pivotal trial initiation | initiate the BIOMAG-III U.S. pivotal trial during 2026 | Mar 2026 | Finally, we commenced the BIOMAG-3 randomized pivotal trial in the U.S. with the first patient procedures completed in June at the MedStar Washington Hospital Center. | Achieved |
| BIOTRONIK Vascular Intervention products constant-currency revenue growth beginning 2026 | 6% or better constant currency revenue growth beginning in 2026 | Dec 2024 | So look, we don't get into product line details, but I think it's safe to say that the legacy -- or the BIOTRONIK BI acquisition revenue base was disproportionately impacted through the integration struggles. | At Risk |
| Acute Care and Interventional Urology strategic divestiture closing | close the Acute Care and Interventional Urology divestiture in the second half of 2026 | Dec 2025 | The strategic divestiture is currently anticipated to be completed in the fourth quarter of 2026, although the timing is dependent on the regulatory approval process and remaining steps to complete the transaction. | On Track |
4 of TELEFLEX INC's 41 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 38 more targets are in the full ledger.
Claimed
- Overall pro forma adjusted constant currency growth was 4.7%.
- Adjusted operating margin reached 19.6%.
- Adjusted EPS was $1.76, a 1.7% increase year-over-year, exceeding expectations.
- Successful close of the OEM divestiture, generating $1.5 billion in proceeds.
- FDA BLA approval for EZPlas freeze-dried plasma, expanding the emergency medicine portfolio.
Qualified
- Interventional business revenue decreased 1% year-over-year, falling short of expectations due to integration delays.
- Adjusted gross margin decreased 280 basis points year-over-year to 61.7%, primarily due to tariffs and the Vascular Intervention business.
- Adjusted operating margin decreased 520 basis points to 19.6% due to gross margin pressure, higher operating expenses, and increased R&D.
- Full-year 2026 pro forma adjusted constant currency revenue growth guidance lowered to 3.5%-4.5% from 4.5%-5.5%.
Price
$129.68 −0.58% · −$0.75
Performance +1.2% 1Y
1Y: $128.13 on 17 Oct 2025 → $129.68. High $142.05 (31 Aug 2026), low $100.34 (20 Jan 2026).
- Previous close
- $130.43
- 52-week range
- $100.34 – $142.05
- One year
- −0.66%
Overview
- Symbol
- TFX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
9 of 13 judged targets kept · 28 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Freesolve BIOMAG-III U.S. pivotal trial initiation | initiate the BIOMAG-III U.S. pivotal trial during 2026 | Mar 2026 | Finally, we commenced the BIOMAG-3 randomized pivotal trial in the U.S. with the first patient procedures completed in June at the MedStar Washington Hospital Center. | Achieved |
| BIOTRONIK Vascular Intervention products constant-currency revenue growth beginning 2026 | 6% or better constant currency revenue growth beginning in 2026 | Dec 2024 | So look, we don't get into product line details, but I think it's safe to say that the legacy -- or the BIOTRONIK BI acquisition revenue base was disproportionately impacted through the integration struggles. | At Risk |
| Acute Care and Interventional Urology strategic divestiture closing | close the Acute Care and Interventional Urology divestiture in the second half of 2026 | Dec 2025 | The strategic divestiture is currently anticipated to be completed in the fourth quarter of 2026, although the timing is dependent on the regulatory approval process and remaining steps to complete the transaction. | On Track |
Claimed
- Overall pro forma adjusted constant currency growth was 4.7%.
- Adjusted operating margin reached 19.6%.
- Adjusted EPS was $1.76, a 1.7% increase year-over-year, exceeding expectations.
- Successful close of the OEM divestiture, generating $1.5 billion in proceeds.
- FDA BLA approval for EZPlas freeze-dried plasma, expanding the emergency medicine portfolio.
Qualified
- Interventional business revenue decreased 1% year-over-year, falling short of expectations due to integration delays.
- Adjusted gross margin decreased 280 basis points year-over-year to 61.7%, primarily due to tariffs and the Vascular Intervention business.
- Adjusted operating margin decreased 520 basis points to 19.6% due to gross margin pressure, higher operating expenses, and increased R&D.
- Full-year 2026 pro forma adjusted constant currency revenue growth guidance lowered to 3.5%-4.5% from 4.5%-5.5%.
The full ledger
Open TELEFLEX INC’s full ledger
A free account opens 5 company ledgers a month. All 41 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Teleflex Q1 FY26 — Portfolio Optimization and Capital Allocation Progress
Read the full callDec 2025 (Q4 FY25) — Feb 26, 2026
Teleflex Q4 FY25 — Strategic Divestitures and Future Growth Focus
Read the full callEvery analysed call
Teleflex earnings calls (TFX)
Financials
What the filings say
Net profit, year on year: −19% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 426 | 442 | 414 | 443 | 567 | 569 | 548 | 570 |
| Operating profit | 72 | 52 | 76 | 91 | -62 | 14 | 20 | 73 |
| Operating margin | 16.9% | 11.9% | 18.3% | 20.6% | −11.0% | 2.4% | 3.7% | 12.8% |
| Interest | 21 | 19 | 19 | 22 | 32 | 28 | 26 | 28 |
| Profit before tax | 131 | -127 | 59 | 71 | -439 | 219 | -4 | 45 |
| Tax rate | 15.0% | −7.8% | 10.9% | 3.5% | 6.8% | −14.1% | −26.4% | 7.5% |
| Net profit | 111 | -137 | 95 | 123 | -409 | -714 | -8 | 100 |
| EPS ($ per share) | 2.38 | -2.95 | 2.08 | 2.77 | -9.24 | -16.15 | -0.18 | 2.29 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 47 | 48 | 48 | 48 | 48 | 48 | 48 | 48 |
| Reserves | 2,428 | 2,825 | 3,096 | 3,518 | 3,817 | 4,110 | 4,116 | 3,150 |
| Total liabilities | 3,738 | 3,331 | 3,816 | 3,117 | 2,906 | 3,092 | 2,820 | 3,822 |
| Fixed assets | 433 | 431 | 474 | 444 | 447 | 480 | 308 | 498 |
| Total assets | 6,278 | 6,310 | 7,153 | 6,872 | 6,928 | 7,533 | 7,098 | 6,947 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 435 | 437 | 437 | 652 | 343 | 206 | 302 | 97 |
| Cash from investing | -196 | -73 | -838 | 157 | — | — | — | — |
| Cash from financing | -206 | -419 | 455 | -716 | -218 | 39 | -422 | 612 |
| Net cash flow | 24 | -56 | 75 | 69 | -153 | -69 | 105 | 126 |
| Capital expenditure | -81 | -103 | -91 | -72 | -79 | -46 | -90 | -95 |
| Free cash flow | 354 | 334 | 346 | 581 | 264 | 160 | 211 | 1 |
TFX revenue by segment
EMEA grew from 20% to 26% of revenue over the last two years.
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Americas | 57% | 101% | 68% | 67% | 61% | 69% | 61% | 61% | -33.6% |
| EMEA | 20% | 20% | 22% | 21% | 26% | 20% | 27% | 26% | -12.5% |
| Asia | 13% | 12% | 11% | 11% | 13% | 11% | 13% | 13% | -14.7% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
33 filings between Jan 13, 2026 and Sep 8, 2026.
Open market
decisions to buy or sellNobody bought or sold TFX on the open market in this window. The filings below are 23 awards and 10 tax withholdings.
Compensation
not trading decisions- 23
- Award — granted as compensation
- 10
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Salmon Sean Director | Award | 674 | $0 |
| Jun 8, 2026 | RANDLE STUART A Director | Award | 995 | $0 |
| Jun 8, 2026 | RANDLE STUART A Director | Award | 4,663 | $0 |
| Jun 8, 2026 | Weidman Jason R. President and CEO | Award | 53,983 | $0 |
| Jun 7, 2026 | RANDLE STUART A Director | Tax withheld | 4,054 | $526.4K |
| May 15, 2026 | HAGGERTY GRETCHEN R Director | Award | 1,090 | $0 |
| May 15, 2026 | Krakauer Andrew A Director | Award | 1,090 | $0 |
| May 15, 2026 | Duncan Candace H Director | Award | 1,090 | $0 |
| May 15, 2026 | Ryu Jaewon Director | Award | 1,090 | $0 |
| May 15, 2026 | Patil Neena M Director | Award | 1,090 | $0 |
| May 15, 2026 | TOKICH MICHAEL J Director | Award | 1,090 | $0 |
| May 9, 2026 | RANDLE STUART A Interim President and CEO | Tax withheld | 289 | $38.5K |
| Mar 4, 2026 | Winters James Corp VP, Mfg and Supply | Tax withheld | 247 | $29.4K |
| Mar 4, 2026 | Hicks Cameron P Corp. VP & Chief HR Officer | Tax withheld | 98 | $11.7K |
| Mar 4, 2026 | Deren John Executive Vice President & CFO | Tax withheld | 229 | $27.3K |
| Mar 4, 2026 | Logue Daniel V. CVP, General Counsel & Secty | Tax withheld | 131 | $15.6K |
| Mar 3, 2026 | Winters James Corp VP, Mfg and Supply | Award | 9,745 | $0 |
| Mar 3, 2026 | Logue Daniel V. CVP, General Counsel & Secty | Award | 3,262 | $0 |
| Mar 3, 2026 | Logue Daniel V. CVP, General Counsel & Secty | Award | 6,591 | $0 |
| Mar 3, 2026 | Hicks Cameron P Corp. VP & Chief HR Officer | Award | 2,447 | $0 |
| Mar 3, 2026 | Hicks Cameron P Corp. VP & Chief HR Officer | Award | 5,649 | $0 |
| Mar 3, 2026 | Deren John Executive Vice President & CFO | Award | 4,604 | $0 |
| Mar 3, 2026 | Deren John Executive Vice President & CFO | Award | 9,180 | $0 |
| Mar 3, 2026 | Winters James Corp VP, Mfg and Supply | Award | 3,262 | $0 |
| Feb 28, 2026 | Logue Daniel V. CVP, General Counsel & Secty | Tax withheld | 484 | $59.1K |
| Feb 28, 2026 | Hicks Cameron P Corp. VP & Chief HR Officer | Tax withheld | 396 | $48.3K |
| Feb 28, 2026 | Deren John Executive Vice President & CFO | Tax withheld | 231 | $28.2K |
| Feb 28, 2026 | Winters James Corp VP, Mfg and Supply | Tax withheld | 661 | $80.7K |
| Feb 23, 2026 | Deren John Executive Vice President & CFO | Award | 161 | $0 |
| Feb 23, 2026 | Winters James Corp VP, Mfg and Supply | Award | 354 | $0 |
| Feb 23, 2026 | Logue Daniel V. CVP, General Counsel & Secty | Award | 443 | $0 |
| Feb 23, 2026 | Hicks Cameron P Corp. VP & Chief HR Officer | Award | 352 | $0 |
| Jan 13, 2026 | RANDLE STUART A Interim President and CEO | Award | 12,325 | $0 |
| Aug 6, 2025 | HAGGERTY GRETCHEN R Director | Purchase | 300 | $34.4K |
| Aug 6, 2025 | HAGGERTY GRETCHEN R Director | Purchase | 200 | $23.0K |
| Aug 5, 2025 | RANDLE STUART A Director | Purchase | 1,000 | $115.9K |
| Aug 5, 2025 | Kelly Liam Chairman, President & CEO | Purchase | 1,500 | $172.6K |
| Aug 5, 2025 | Ryu Jaewon Director | Purchase | 1,500 | $172.5K |
| Aug 5, 2025 | Krakauer Andrew A Director | Purchase | 1,000 | $115.3K |
| May 9, 2025 | Krakauer Andrew A Director | Award | 1,051 | $0 |
| May 9, 2025 | RANDLE STUART A Director | Award | 1,051 | $0 |
| May 9, 2025 | Klasko Stephen K. M.D. Director | Award | 1,357 | $0 |
| May 9, 2025 | Ryu Jaewon Director | Award | 1,051 | $0 |
| May 9, 2025 | HAGGERTY GRETCHEN R Director | Award | 1,051 | $0 |
| May 9, 2025 | Patil Neena M Director | Award | 1,051 | $0 |
| May 9, 2025 | HEINMILLER JOHN C Director | Award | 1,051 | $0 |
| May 9, 2025 | Duncan Candace H Director | Award | 1,051 | $0 |
| May 5, 2025 | Duncan Candace H Director | Tax withheld | 4,705 | $594.8K |
| May 5, 2025 | Duncan Candace H Director | Option exercise | 4,833 | $594.7K |
| Apr 1, 2025 | POWELL THOMAS E Executive Vice President & CFO | Disposition to issuer | 655 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TELEFLEX INC
Free account. Everything above stays public.
Write why you follow TELEFLEX INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading